Printer Friendly


 NEW YORK, June 23 /PRNewswire/ -- In the final program of "On The Issues," panelists consider the hypothetical dilemma facing "Pharmasee Corporation." Pharmasee believes it can develop an effective oral contraceptive for men, but further research and development is costly, the political climate might be hot and the risk of lawsuits may outweigh potential profits. Consumer advocates confront corporate leaders, and corporate defense attorneys take on plaintiff attorneys, in a lively debate considering whether product liability suits are protecting the public or stifling the development of useful new products.
 Among the issues discussed are:
 -- Can product warnings protect a company from liability suits?
 -- Are juries qualified to evaluate highly technical evidence?
 -- Do liability suits stimulate product improvements and safety?
 -- Do sealed settlements deny the public safety information?
 -- Does the product liability system inhibit the development of new
 Michael V. Ciresi Partner in the Minneapolis law firm of Robins,
 Kaplan, Miller and Ciresi, Ciresi focuses his
 practice on trial work and consulting in the
 areas of business and commercial litigation
 and product liability. He was lead counsel in
 the Dalkon Shield litigation.
 Anne E. Cohen Associate at the international law firm of
 Debevoise & Plimpton.
 Roxanne Barton Conlin President of the Association of Trial Lawyers
 of America, Conlin has served as general
 counsel and president of the Legal Defense and
 Education Fund for NOW. She was the first
 woman nominated for governor in Iowa.
 William D. Fay Executive director of the Product Liability
 Coordinating Committee, an organization
 representing a coalition of over 700,000
 businesses that lobbies for a uniform federal
 product liability statute.
 Pamela Gilbert Director of Public Citizen's Congress Watch,
 the Capitol's largest consumer advocacy
 organization, Gilbert has played a leading
 role in the defeat of legislation to weaken
 product liability laws.
 Peter Huber Senior fellow of the Manhattan Institute for
 Policy Research, Huber is a lawyer and writer
 with expertise in liability law.
 Kenneth Jost Jost is a legal affairs journalist who has
 covered this field since 1970 as a reporter,
 editor and contributing writer. He is also an
 adjunct professor at Georgetown University Law
 School where he teaches media law.
 Linda Lipsen As legislative director at Consumers Union,
 the non-profit advocacy organization that
 publishes Consumer Reports, Lipsen represents
 the consumer interest in legislative, judicial
 and regulatory proceedings.
 J. Bruce Llewellyn Chairman of Philadelphia Coca-Cola Bottling
 Company, America's third largest black-owned
 business, and chairman of Garden State
 Cablevision Inc.
 Elaine Reiss An advertising agency executive and attorney,
 Reiss is senior vice president of the Council
 of Better Business Bureaus.
 Victor E. Schwartz Senior partner at the law firm of Crowell &
 Moring, Schwartz is the co-author of the most
 widely used tort casebook in the United
 States. His practice includes product
 liability loss prevention.
 Maria Elena Torano President and CEO of META, a government
 contractor and one of the top 200 Hispanic
 businesses in the United States.
 James Vincent Chairman and CEO of Biogen, Inc., a pioneering
 biotechnology company that has developed
 hepatitis vaccines and treatments.
 -0- 6/23/93
 /CONTACT: Jan DuPlain, WETA/26, 703-998-2627; Denise Crawford, WNET/Thirteen, 212-560-4919; or Bill Cleary, Price Waterhouse, 202-728-9780, for "On The Issues"/

CO: WETA/26; Thirteen/WNET; Price Waterhouse ST: New York IN: ENT MTC SU:

IH-DC -- DC004 -- 4962 06/23/93 11:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 23, 1993

Related Articles
Aradigm Announces Expansion of Clinical Programs and Issuance of Eight U.S. Patents.
/C O R R E C T I O N -- Biopure Corporation/.
Cerus U.S. Phase 3 Trial of Platelet Pathogen Inactivation System Moves Forward on Monitoring Board Report.
Cellegy Pharmaceuticals Granted Anogesic Patent in Europe.
Cellegy Pharmaceuticals Granted Canadian Patent for Anogesic(R).
Vion Pharmaceuticals, Inc. Announces Issuance of Broad TAPET(R) Patent.
Avigen Granted Orphan Drug Status for Its Hemophilia Product.
AltaRex Completes Pivotal OvaRex(R) Clinical Trial for Primary Analysis.
AltaRex Achieves Major Manufacturing Milestone for OvaRex(R) MAb; -- Expects to Commence Pharmacokinetic Study --.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters